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Abstract
Exposure to rotenone in vivo results in selective degeneration of dopaminergic neurons and 
development of neuropathological features of Parkinson's disease. As rotenone acts as an inhibitor 
of mitochondrial respiratory complex I, we employed oxidative lipidomics to assess oxidative 
metabolism of a mitochondria-specific phospholipid, cardiolipin, in substantia nigra of exposed 
animals. We found a significant reduction of oxidizable PUFA-containing cardiolipin molecular 
species. We further revealed increased contents of mono-oxygenated cardiolipin species at late 
stages of the exposure. Notably, linoleic acid in sn-1 position was the major oxidation substrate 
yielding its mono-hydroxy- and epoxy-derivatives whereas more readily “oxidizable” fatty acid 
residues (arachidonic, docosahexaenoic acids) – remained non-oxidized. Elevated levels of PUFA 
cardiolipins were detected in plasma of rats exposed to rotenone. Characterization of oxidatively 
modified cardiolipin molecular species in substantia nirga and detection of PUFA-containing 
cardiolipin species in plasma may contribute to better understanding of the Parkinson's disease 
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pathogenesis and lead to the development of new biomarkers of mitochondrial dysfunction 
associated with this disease.
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Introduction
Parkinson's disease is a neurodegenerative disorder in the elderly characterized by the loss of 
dopaminergic neurons in substantia nigra (SN) [1]. Mitochondrial dysfunction and oxidative 
stress are believed to be important contributors to the neuronal loss and the pathogenesis of 
Parkinson's disease [2-6]. Decreased activity of mitochondrial complex I [7], reduced 
amounts of GSH [8], protein modification [9], DNA damage [10] and lipid oxidation [11] 
have been documented in the substantia nigra compacta of patients with Parkinson's disease 
in many studies. While polyunsaturated phospholipids are the major substrates for oxidative 
modifications [12], evaluation of lipid peroxidation products has been restricted to detection 
of secondary oxidation products such as 4-hydroxy-2-nonenal [13, 14] and essential 
information on molecular targets, particularly specific polyunsaturated molecular species of 
phospholipids undergoing oxidation and leading to mitochondrial dysfunction and their 
association with Parkinson's disease, is lacking.
Given that oxidation products formed from polyunsaturated molecular species of a 
mitochondria-specific phospholipid, cardiolipin (CL) have been identified as important cell 
death signals [12, 15], their systematic analysis in PD-relevant samples may be particularly 
important. However, reliable identification and quantitation of these products even using 
sensitive contemporary LC/MS protocols, is challenging due to the inherent instability, fast 
metabolic conversions as well as high diversification of oxidized species resulting in their 
low steady-state concentrations [16]. We have developed several advanced techniques of 
oxidative lipidomics that allowed physical separation of oxidized and non-oxidized 
phospholipids as well as accurate identification and quantitative analysis of oxygenated 
molecular species of phospholipids by using liquid chromatography (LC) or high-
performance thin-layer chromatography (HPTLC) protocols [17-19] along with different 
versions of mass spectrometry (MS) combined with enzymatic hydrolysis of fatty acid 
residues from modified phospholipids [20]. Here, using a rat rotenone model of Parkinson's 
disease [21] and oxidative lipidomics approach we were able, for the first time, to identify 
and quantitatively characterize oxygenated molecular species of CL formed in dysfunctional 
mitochondria in SN as well as in CL in plasma.
Methods
Rat rotenone model
The Institutional Animal Care and Use Committee of the University of Pittsburgh approved 
all experiments utilizing animals. Male Lewis rats (7-9 months old, Charles River) were 
injected intraperitoneally with vehicle or 3.0 mg/kg/day rotenone (Sigma-Aldrich) either 
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once, for five daily injections or treated to parkinsonian endpoint. We chose to evaluate one 
and five daily injection paradigms because we have previously detected mitochondrial DNA 
damage in the substantia nigra and peripheral tissues following rotenone treatment at these 
time points [22, 23]. Animals treated with rotenone to parkinsonsian endpoint recapitulate 
many of the key pathological features of PD [24, 25]. Endpoint rotenone treated animals 
(10-14 days) were sacrificed when animals displayed behavioral features including 
bradykinesia, postural instability/gait disturbances and rigidity. Rat brains were first 
removed from the skull and rinsed in cold 1X PBS to remove any surface blood. Brains were 
placed on a cold petri dish and cut in half into the right and left hemisphere. Using a blade 
and forceps precise micro-dissection of the ventral midbrain was performed and the tissue 
was flash frozen in liquid nitrogen and stored at -80°C.
Extraction of lipids
Lipids were extracted from SN and plasma using the Folch and Bligh Dyer procedures, 
respectively [26, 27]. Lipid phosphorus was determined by a micro-method [28].
Analysis of esterified fatty acids
To release esterified fatty acids, total lipids were treated with either phospholipase A1 
(PLA1) from Thermomyces lanuginosus (10 μl/μmol of phospholipids) (Sigma-Aldrich, St. 
Louis, MO) or phospholipase A2 (PLA2) from porcine pancreas (10 U/μmol of 
phospholipids) (Sigma-Aldrich, St. Louis, MO) in 0.5 M borate buffer, pH 9.0 containing 20 
mM cholic acid, 2 mM CaCl2 and 100 μM DTPA for 60 min at 37°C. Under these 
conditions, almost 99% of phospholipids were hydrolyzed. Liberated oxygenated and non-
oxygenated fatty acids were separated from lipids and lyso-lipids by solid phase extraction 
using phospholipid removing plates (Phenomenex, Torrance, CA) and analyzed by LC/MS 
as described [29]. Briefly, LC/MS in negative mode was performed using a Dionex 
Ultimate™ 3000 HPLC coupled on-line to a Q-Exactive hybrid quadrupole-orbitrap mass 
spectrometer (ThermoFisher Scientific, San Jose, CA). Fatty acids were separated on a 
reverse phase column (C18 Luna, 3 μm, 150 × 2 mm, Phenomenex, Torrance, CA) with flow 
rate 0.2 mL/min using gradient solvents containing 5 mM ammonium acetate (A: 
tetrahydrofuran/methanol/water/CH3COOH, 25:30:50:0.1 (v/v/v/v) and B: methanol/water 
90:10 (v/v)). The column was eluted first 3 min isocratically at 50% B, from 3 to 23 min 
with a linear gradient from 50% solvent B to 98% solvent B, then 23-40 min isocratically 
using 98% solvent B, 40-42 min with a linear gradient from 98% solvent B to 50% solvent 
B, 42-60 min isocratically using 50% solvent B for equilibration of the column. Standards of 
oxygenated fatty acids were purchased from Cayman Chemical Co. (Ann Arbor, MI).
Analysis of CL
LC/MS was performed as previously described [29]. Briefly, LC/MS in negative mode was 
performed using a Dionex Ultimate™ 3000 HPLC coupled on-line to a linear ion trap mass 
spectrometer (LXQ, ThermoFisher Scientific, San Jose, CA). Thus, m/z values for CL 
molecular species were presented to 1 decimal place. Total lipids were separated on a 
normal phase column (Silica Luna 3 μm, 100A, 150×2 mm, (Phenomenex, Torrance CA)) 
with flow rate 0.2 mL/min using gradient solvents containing 5 mM CH3COONH4 (A – n-
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hexane:2-propanol:water, 43:57:1 (v/v/v) and B - n-hexane:2-propanol:water, 43:57:10 
(v/v/v). Tetra- myristoyl – CL (TMCL) (Avanti polar lipids, Alabaster, AL) was used as an 
internal MS standard.
Analysis of oxygenated CL
CL was separated by two-dimension high-performance thin-layer chromatography (2D-
HPTLC) [30] and CL and oxygenated CL were analysed by LC/MS as described [18]. To 
prevent lipid oxidation during separation, chromatography was performed under N2 
conditions on diethylenetriaminepentaacetic acid (DTPA) treated silica plates (5×5cm, 
Whatman). LC/MS in negative mode was performed using a Dionex UltimateTM 3000 
RSLCnano system coupled online Q-Exactive hybrid quadrupole-orbitrap mass 
spectrometer (ThermoFisher Scientific, San Jose, CA) using a C8 column (Luna 3 μm, 100 
Å, 150 × 2mm, Phenomenex, Torrance, CA) with flow rate 0.15 mL/min using an isocratic 
solvent system consisting of 2-propanol: water: triethylamine: acetic acid, 45:5:0.25:0.25, 
v/v. The resolution was set up at 140000 which corresponds to 5 ppm in m/z measurement 
error. Thus, m/z values for CLs and their oxidation species were presented to 4 decimal 
places. TMCL (Avanti polar lipids, Alabaster, AL) was used as an internal MS standard. 
TMCL molecular species is not usually present in the brain (and other tissues) and does not 
interfere with the endogenous CLs and widely used as an internal standard [31]. The 
ionization efficiencies of individual molecular species of CLs, particularly of those with 
differing fatty acid chains, may be different. To minimize the potential inaccuracies, the 
tuning of mass spectrometers was performed using TLCL, (C18:2)4-CL. In addition, TLCL 
was also utilized as a reference standard to build calibration curves employed for 
quantitative assessments of CLs in the brain. Finally, we were able to compare the total 
amounts of CLs in SN samples based on LC-MS analysis and summation of individual 
molecular species with that obtained from the direct determinations after 2D-HPTLC 
separation of total phospholipid extracts. These comparisons showed good co-incidence of 
the CL amounts determined in two independent ways.
Statistics
The results are presented as mean ± S.D. values from at least three experiments, and 
statistical analyses were performed by either paired/unpaired Student's t-test or one-way 
ANOVA. The statistical significance of differences was set at p< 0.05 
Results
Rotenone is a highly lipophilic compound that can crosses the blood-brain barrier [32, 33]. 
Its toxicity mechanisms are mostly associated with the binding to and inhibiting electron 
transport at the level of complex I and generation of superoxide radicals [15, 34, 35]. These 
mitochondria-related effects lead to selective degeneration of dopaminergic neurons and 
produce neuropathological features of Parkinson's disease [21]. Therefore, our oxidative 
lipidomics efforts to detect mitochondria-specific modification of lipids were focused on the 
analysis of CLs in SN of rats exposed to rotenone. The flow-chart representing our 
analytical approach is shown in Fig. 1.
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Because of high diversification of oxidatively modified phospholipids with potentially low 
content of each of them, we chose to simplify the analytical task by reducing the number of 
oxygenated molecular species. To this end, we treated the total lipid extracts with either 
PLA1 or PLA2 to release fatty acid residues from sn-1 and sn-2 position of phospholipids, 
respectively. This allowed the detection of oxidation products in a limited number of 
molecular species of oxidizable polyunsaturated fatty acids (PUFA). PUFA were mainly 
represented by linoleic (C18:2), arachidonic (C20:4), and docosahexaenoic (C22:6) acids and 
predominantly localized in sn-2 position (Fig. 2). Surprisingly, while the content of PUFA in 
sn-1 position was significantly lower than in sn-2, oxygenated fatty acid species were 
released almost exclusively upon PLA1 treatment (Fig. 3). Furthermore, among the PUFAs 
released, linoleic acid (C18:2, with 2 double bonds) underwent oxidative modification to 
mono-hydroxy- (HODE) and epoxy- (EpOME) derivatives (Fig. 3), whereas more 
polyunsaturated, hence more readily “oxidizable” fatty acid residues such as C20:4, and C22:6 
– remained non-oxidized. A substantial increase of epoxy-molecular species of C18:2 was 
detected on day 5 and parkinsonsian endpoint (Fig. 3); however the changes in the content 
of hydroxy-species of C18:2 were significant only at parkinsonsian endpoint. No 
accumulation of oxygenated C18:2 was observed at day 1 of exposure (Fig. 3). No 
oxygenated PUFAs were detected in samples obtained from rats exposed to rotenone and 
treated with PLA2 (data not shown). In major classes of phospholipids including 
phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine, oxidizable 
polyunsaturated fatty acids (C18:2, C20:4 and C22:6) occupy predominantly the sn-2 position 
whereas in CL they can be equally distributed between sn-1 and sn-2 positions [18]. This 
suggests that oxygenated esterified C18:2 detected in SN of rotenone treated rats likely 
originated from the sn-1 position of CL.
Therefore, we further specifically focused on the analysis of CLs in SN. Using normal phase 
LC followed by full MS and MS2 analysis, we identified oxidizable CL molecular species 
containing fatty acids with two – six double bonds (Table 1, Figs. 4A, 4B). Quantitative 
assessments revealed a substantial reduction of these species in SN of rotenone exposed rats 
at all-time points studied compared to control animals (Fig. 4C). Notably, all these 
polyunsaturated CL species contained at least one C18:2 residue. No changes in the CL 
content in from cortex of the same rats were detected (data not shown). Therefore, we 
suggested that decrease in the content of oxidizable CL was linked to rotenone-induced 
damage of mitochondria in SN.
Assuming that lipid peroxidation can contribute to the depletion of oxidizable CL we further 
characterized oxygenated CL species in SN. CLs were pre-separated by HPTLC and 
subjected to reverse phase LC to resolve non-oxidized vs oxidized CL species after which 
high mass accuracy MS was employed to identify CL oxygenated species (Fig. 5). We 
detected significantly increased content of mono-oxygenated CL species at parkinsonsian 
endpoint (Fig. 6). Quantitative analysis revealed accumulation of several mono-oxygenated 
CL species (m/z 1443.9903, m/z 1446.0038, m/z 1472.0189, m/z 1491.9891, m/z 
1494.0033, m/z 1515.9889 and m/z 1518.0026) (Fig.6) which originated from oxidizable CL 
species (m/z 1427.9966, m/z 1430.0077, m/z 1456.0260, m/z 1475.9943, m/z 1478.0067, 
m/z 1499.9929 and m/z 1502.0061). Notably, all of these species were reduced by rotenone 
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exposure and contained at least one C18:2 residue (Table 1, Fig. 3). No accumulation of 
oxygenated CL in SN on day 1 was detected (data not shown).
Assuming that mitochondria with their CLs and oxidized CLs can be released from damaged 
cells into extracellular environments and act as damage associated molecular patterns 
(DAMPs) [36] we performed analysis of CL in plasma of rats at two time points (day 1 and 
day 5) after the exposure to rotenone. MS analysis revealed the increase of relative intensity 
for CL molecular species with m/z 1425.9832, m/z 1427.9962, m/z 1430.0088, m/z 
1454.0051, m/z 1456.0249, m/z 1475.9922 and m/z 1478.0150 (Fig. 7). Relative intensity 
for several individual CL molecular species as well as their total content were significantly 
higher on days 1 and 5 compared to respective controls (Fig 7B, C). All CL in plasma were 
represented by non-oxygenated molecular species. The sensitivity of LC/MS assay for 
oxygenated CL is approximately 10 nM. Given that the observed levels of oxygenated CL in 
rotenone-treated rats constituted only 0.2% of its total content in the brain, the expected 
increased levels in plasma would be on the order of 0.3 nM. Assuming that metabolic 
conversions of oxygenated CL (for example by lipoprotein associated Lp-PLA2 [18]) would 
result in its hydrolysis, the contents of oxygenated CL would be even lower.
Discussion
Oxidatively modified phospholipids have been recognized as important signals in acute 
injury and chronic diseases [37-39]. CL is a negatively charged phospholipid with four fatty 
acid residues [40]. In normal conditions CL is found exclusively in the inner-mitochondrial 
membrane where it accounts for 25% of all phospholipids [41] and essential for normal 
functions of many proteins, including the activity of respiratory complexes [42-45]. 
Accumulation of oxygenated CL molecular species and their hydrolysis products has been 
demonstrated for acute brain injury caused by trauma and cardiac arrest [46, 47], hyperoxic 
and nanoparticle induced lung injury [48, 49] as well as acute irradiation syndrome [18, 29, 
50]. Polyunsaturated CLs in the brain have been considered not only as oxidation substrates 
[12] but also as a source of oxygenated lipid mediators [18 , 46, 51].
Rotenone - a known inhibitor of complex I in mitochondria – has been used to mimic 
clinical features of Parkinson's disease [1]. The rotenone model is characterized by slow and 
progressive loss of dopaminergic neurons and formation of Lewy bodies in SN [1]. 
Degeneration of dopaminergic neurons in SN has been long associated with mitochondrial 
dysfunction. Given that disrupted electron transport may be linked to the enhanced ROS 
(reactive oxygen species) production in mitochondria [52], we sought to test whether this 
would result in oxidative modifications of a susceptible phospholipid target, CL, highly 
concentrated in close proximity to complex I in the inner mitochondrial membrane [53, 54]. 
Using the rat rotenone model of Parkinson's disease, here, we demonstrate, for the first time, 
the accumulation of CL oxygenated species in SN.
Two major pathways triggered in dysfunctional mitochondria - mitophagy and apoptosis – 
may be involved in responses of dopaminergic neurons to rotenone in SN [55-57]. For both 
pathways CLs have been recognized as signaling molecules [16, 58]. In the case of pro-
survival mitophagy CL is externalized to the outer leaflet of the outer mitochondrial 
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membrane but does not undergo oxidation [58]. The externalized CL acts as a signal 
recognized by LC3 to facilitate the elimination of damaged mitochondria, and rescue the cell 
[58]. In contrast, accumulation of oxygenated CL species has been identified as an early 
event in the execution of apoptotic program [15] resulting in the release of cyt c into the 
cytosol and, activation of caspases and cell death [15]. Our oxidative lipidomics protocols 
revealed the early loss of oxidizable linoleic acid-containing CL species (on day 1 and 5 
after exposure to rotenone) and accumulation of CL oxidation products in the same 
molecular species in SN on the parkinsonsian endpoint. Of note, in this model animals 
received rotenone daily, thus the total dose of rotenone was increasing during the exposure. 
This is compatible with our previous observations in vitro demonstrating that small doses of 
rotenone stimulated mitophagy in primary cortical neurons without CL oxidation [58]. 
However, at higher doses, rotenone caused CL oxidation and activation of the apoptotic cell 
death pathway. It is tempting to speculate that at the early time point, the mitophageal 
pathway was activated in SN neurons as a rescue mechanism which transitioned to 
triggering the apoptotic death as the damage was enhanced by increasing doses of rotenone 
at later time points.
Analysis of CL oxidation products in SN revealed unusual features of rotenone-associated 
oxidation: i) exclusive accumulation of oxygenated C18:2 in sn-1 rather than sn-2 position 
and ii) selective generation of mono-oxygenated CL species. In line with this, our previous 
studies identified C18:2, located in sn-1 position of CL as the major oxidation substrate in 
rotenone-treated lymphocytes [20]. Notably, mono-oxygenated-CL species were the major 
products detected in rotenone-exposed lymphocytes [20]. While the mechanisms of this 
unusual specificity towards C18:2 species of CLs remain to be elucidated, they are indicative 
of enzymatic rather than random stochastic free radical oxidation pathways. One of the 
candidate catalysts in oxidation of CL is cytochrome c with its established role during 
apoptosis [15]. Oxidizing equivalents (O2•- -->H2O2) formed in mitochondria during 
apoptosis feed the peroxidase activity of cytochrome c/CL complexes resulting in the 
selective depletion of oxidizable CL species in mitochondria and the accumulation of 
oxygenated CLs [15]. Alternatively, 12/15-lipoxygenase driven mechanisms may be enacted 
in damaged mitochondria to cause CL oxidation [59]. In the latter case, however, the 
selectivity to phospholipid substrates (CLs) should be less pronounced. Following oxidation, 
the hydrolysis reactions – possibly catalyzed by phospholipase A2 – can be involved in 
depletion of oxidizable CL species in SN of rotenone-treated rats. Recently, we discovered a 
new biosynthetic pathway for lipid mediators activated in vivo after acute tissue injury 
realized by oxidation and hydrolysis of oxygenated CLs species by mitochondrial Ca2+-
independent iPLA2γ [18]. Several reports indicate that iPLA2-Vi, a calcium-independent 
PLA2, may be implicated in the pathogenesis of Parkinson's disease [60-62]. Mutation of 
PLA2G6, encoding calcium-independent PLA2, is characteristic of PD and results in the 
suppression of the enzymatic activity [60]. There are only few publications on the effect of 
rotenone on iPLA2 activity in mitochondria. In studies on isolated lung and liver 
mitochondria, rotenone treatment caused the release of PUFA which was partially sensitive 
to R-BEL [63, 64]. Our in vivo studies, however, did not document higher levels of free 
fatty acids or oxygenated free fatty acids in SN of rotenone-treated rats vs control rats. 
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Accordingly, with the exception of lyso-phosphatidylcholine, no accumulation of other lyso-
phospholipids have been observed.
While apoptosis-driven CL oxidation may be accountable for the observed accumulation of 
oxidized CL, it is likely that non-apoptotic cell death pathways are also triggered in 
rotenone-treated animals resulting in the release of damaged mitochondria. This may explain 
the detected higher levels of PUFA CL species in plasma. Indeed, execution of necroptotic 
program has been shown to trigger release of mitochondria into extra-cellular compartments 
[65].
In conclusion, we demonstrated that exposure of rats to rotenone causes depletion of PUFA 
CL and accumulation of mono-oxygenated CL species in SN and the emergence of elevated 
levels of CL in plasma. These metabolic CL changes could reflect rotenone-induced 
mitochondrial dysfunction including mitophageal response at the early time points and 
enzymatic CL oxidation during execution of programmed cell death pathways (apoptosis, 
necroptosis) at the later stages after the exposure. Characterization of oxidatively modified 
CL molecular species in SN and detection of PUFA-containing CL species in plasma may 
contribute to better understanding of the Parkinson's disease pathogenesis and lead to the 
development of new biomarkers of mitochondrial dysfunction associated with this disease.
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The flowchart representing analytical approach to assess CL and its oxygenated species in 
plasma and SN.
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Profile of fatty acids liberated from total phospholipids extracted from SN by either PLA1 
(A, sn-1 position) or PLA2 (B, sn-2 position). SFA – saturated fatty acids, MUFA – 
monounsaturated fatty acids, PUFA – polyunsaturated fatty acids; C18:2 - octadecadienoic 
acid (linoleic acid); C18:3 - octadecatrienoic acid, C20:2 – eicosadienoic acid, C20:3 - 
eicosatrienoic acid, C20:4 - eicosatetraenoic acid (arachidonic acid), C20:5 - eicosapentaenoic 
acid, C22:5 - docosapentaenoic acid, C22:6 - docosahexaenoic acid.
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Quantitative assessment of oxygenated C18:2 (octadecadienoic acid) liberated by PLA1 from 
SN total phospholipids. HODE – hydroxy-species of C18:2, EpOME- epoxy-species of C18:2. 
Released oxygenated fatty acids were analyzed by reverse phase LC/MS after solid phase 
extraction. Data are normalized (A) per nmol of total phopsholipids (PLs) and (B) per nmol 
of cardiolipin (CL).
Tyurina et al. Page 14














Assessment of CL in SN by normal phase LC/MS. A. Typical normal phase LC/MS 
chromatogram of phospholipids and full mass spectrum of CL (insert) extracted from SN 
obtained from control rats. Data were acquired in negative mode. CL - cardiolipin, PA - 
phosphatidic acid, PC - phosphatidylcholine, PE - phosphatidylethanolamine , PG - 
phosphatidylglycerol, PI - phosphatidylinositol, PS - phosphatidylserine, SM - 
sphingomyelin. B. MS2 fragmentation of CL molecular ions with m/z 1427.9 (upper panel) 
and m/z 1502.0 (lower panel). C. Quantitative assessments of CL in SN of rotenone exposed 
Tyurina et al. Page 15













rats. The data are presented as rotenone-induced decreases in the amounts of oxidizable CL 
molecular species.
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Detection and identification of CL oxygenated species in rat SN. Typical HPTLC of total 
lipids, LC/MS profile and mass spectra of CL and its oxygenated species obtained from SN 
of rat exposed to rotenone (parkinsonian endpoint). CL was isolated by 2D-HPTLC. The CL 
fraction was then subjected to reverse phase LC/MS analysis using a C8 column (4.6 mm × 
15 cm). CL and oxygenated CL were separated using an isocratic solvent system (see 
method section). Under these conditions, oxygenated CL eluted prior to CL. Molecular 
species of oxygenated CL were identified as mono-oxygenated species based on exact m/z 
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ratios. CL - cardiolipin, FFA – free fatty acids, NL – neutral lipids, PA - phosphatidic acid, 
PC - phosphatidylcholine, PE - phosphatidylethanolamine, PG - phosphatidylglycerol, PI - 
phosphatidylinositol, PS - phosphatidylserine, SM - sphingomyelin.
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Quantitative assessment of total (A) and individual oxygenated molecular species of CL (B) 
in SN of control and rotenone treated rats. V-vehicle; R-rotenone. Molecular species with 
m/z 1443.9903, m/z 1446.0038, m/z 1472.0189, m/z 1491.9891, m/z 1494.0033, m/z 
1515.9889, m/z 1518.0026 are originated from molecular species with m/z 1427.9966, m/z 
1430.0077, m/z 1456.0260, m/z 1475.9943, m/z 1478.0067, m/z 1499.9929, m/z 1502.0061, 
respectively, after addition of one oxygen. Data are mean ± SD, n=4-5. *p<0.05 vs 
respective control (vehicle).
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Detection, identification and quantification of CL in rat plasma. Plasma lipids were 
separated by normal phase LC and detected by using orbitrap Q-Exactive. A. Typical mass 
spectra of CL obtained from control rats and rats exposed to rotenone. Quantitative 
assessment of CL (B) and its individual molecular species (C) in rat plasma. V-vehicle; R-
rotenone. Data are means ± SD, n=3-5. *p<0.05 vs respective control (vehicle). Mass 
spectra of CL were acquired using a Q-Exactive orbitrap mass spectrometer. Thus, m/z 
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values for CL species were presented to 4 decimal places. Arrows indicate the CL species 
that accumulated in plasma.
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Table 1
Major CL and CL ox species detected in substantia nigra and plasma from rats exposed to rotenone.













1454.0059 72:5 18:1/18:1/18:1/18:2 1470.0074 1454.0051


























CL – cardiolipin; CN and DB refer to the total carbon atoms in the fatty acid chains and total number double bonds, respectively; ND – not 
detected
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